BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24999841)

  • 1. ISG12a mediates cell response to Newcastle disease viral infection.
    Liu N; Long Y; Liu B; Yang D; Li C; Chen T; Wang X; Liu C; Zhu H
    Virology; 2014 Aug; 462-463():283-94. PubMed ID: 24999841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus.
    Wilden H; Schirrmacher V; Fournier P
    Int J Oncol; 2011 Aug; 39(2):493-504. PubMed ID: 21567079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death.
    Elankumaran S; Rockemann D; Samal SK
    J Virol; 2006 Aug; 80(15):7522-34. PubMed ID: 16840332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro.
    Song DZ; Liang Y; Xiao Q; Yin J; Gong JL; Lai ZP; Zhang ZF; Gao LX; Fan XH
    Anat Rec (Hoboken); 2013 Oct; 296(10):1552-60. PubMed ID: 23959779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.
    Puhlmann J; Puehler F; Mumberg D; Boukamp P; Beier R
    Oncogene; 2010 Apr; 29(15):2205-16. PubMed ID: 20101224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
    Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
    Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Newcastle disease virus (NDV) V protein enhances NDV production kinetics in chicken embryo fibroblasts.
    Jang J; Hong SH; Choi D; Choi KS; Kang S; Kim IH
    Appl Microbiol Biotechnol; 2010 Feb; 85(5):1509-20. PubMed ID: 19730851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.
    García-Romero N; Palacín-Aliana I; Esteban-Rubio S; Madurga R; Rius-Rocabert S; Carrión-Navarro J; Presa J; Cuadrado-Castano S; Sánchez-Gómez P; García-Sastre A; Nistal-Villan E; Ayuso-Sacido A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32516884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
    Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
    BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
    Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
    Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens.
    Susta L; Cornax I; Diel DG; Garcia SC; Miller PJ; Liu X; Hu S; Brown CC; Afonso CL
    Microb Pathog; 2013; 61-62():73-83. PubMed ID: 23711962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity.
    Walter RJ; Attar BM; Rafiq A; Tejaswi S; Delimata M
    JOP; 2012 Jan; 13(1):45-53. PubMed ID: 22233946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
    Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
    J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a.
    Yang D; Meng X; Xue B; Liu N; Wang X; Zhu H
    PLoS One; 2014; 9(4):e94501. PubMed ID: 24727952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity.
    Fournier P; Arnold A; Wilden H; Schirrmacher V
    Int J Oncol; 2012 Mar; 40(3):840-50. PubMed ID: 22102168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
    Apostolidis L; Schirrmacher V; Fournier P
    Int J Oncol; 2007 Nov; 31(5):1009-19. PubMed ID: 17912426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newcastle disease virus as an oncolytic agent.
    Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
    Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus.
    Fournier P; Wilden H; Schirrmacher V
    Int J Oncol; 2012 Jan; 40(1):287-98. PubMed ID: 21971670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy.
    Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D
    Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.